Dr. Reddy's Laboratories Ltd (RDY) Stock

About Dr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Ltd is led by CEO Erez Israeli, employs 27,527 people, headquartered in Hyderabad, IN, publicly traded since 2001.

Dr. Reddy's Laboratories Ltd (RDY) stock trades at $13.21 with a market capitalization of $11.00B. The stock is valued at a price-to-earnings (P/E) ratio of 30.37, price-to-book of 2.62, price-to-sales of 3.03. Over the past 52 weeks the stock has ranged between $11.36 and $15.67, and currently trades 15.7% below its 52-week high. It pays a dividend yielding 0.65%.

On profitability, Dr. Reddy's Laboratories Ltd generates a return on equity (ROE) of 8.88%, return on capital employed of 8.43%, an operating margin of 13.83%, a net profit margin of 10.00%.

Dr. Reddy's Laboratories Ltd by the numbers, 2017–2026

Between 2017 and 2026 Dr. Reddy's Laboratories Ltd reported revenue of $140.8B rising to $353.5B, a change of +151.0% across 10 years. Compounded, revenue has grown 168.0% a year over five years, 12.9% over three, 8.6% over the last twelve months. Net profit rose to $45.1B.

Operating margin went from 9.6% in 2017 to 13.8% in 2026, a gain of 4.2 percentage points. The most recent net margin is 10.00%. On a trailing twelve-month basis to Jun '26, revenue is $332.8B and net profit $33.2B.

Borrowings rose from $49.2B to $75.8B, cash from operations was $56.6B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 16.2% over five years, and was 12.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Dr. Reddy's Laboratories Ltd (RDY) — frequently asked questions